Stock listing
OTC:ESALF Eisai Co., Ltd. Stock
US listing (OTC) of Eisai Co., Ltd. · home listing Tokyo:4523
Follow Eisai Co., Ltd. into a list and get an email when it puts out news.
Share price · OTC:ESALF
$33.06 USD +0.48 (+1.5%)
Close on Nov 16, 2026
- Day range
- $33.06 – $33.06 USDNov 16, 2026
- Volume
- 200 sharesNov 16, 2026
- Market cap
- $9.33B USDAt the close on Nov 16, 2026 · price × 282.2M shares outstanding
- 52-week range
- $23.88 – $35.00 USDLowest and highest trades, Nov 18, 2025 – Nov 16, 2026
- Traded on an average day
- $17,006 USDMedian day 0 shares · 24 days with no trades · last 3 months, Aug 18, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:ESAIY | $8.28 USD | +0.06 (+0.7%) | 500 | $8.25 | $8.28 | $8.25 | $8.22 | Close on Nov 20, 2026 |
| OTC:ESALF | $33.06 USD | +0.48 (+1.5%) | 200 | $33.06 | $33.06 | $33.06 | $32.58 | Close on Nov 16, 2026 |
| Frankfurt:EII | €29.71 EUR | -1.04 (-3.4%) | — | €29.61 | €29.71 | €29.61 | €30.75 | Close on Nov 20, 2026 |
| Munich:EII | €30.06 EUR | +0.01 (0.0%) | — | €30.06 | €30.06 | €30.06 | €30.05 | Close on Nov 20, 2026 |
| Dusseldorf:EII | €29.49 EUR | -0.27 (-0.9%) | — | €30.00 | €30.00 | €29.49 | €29.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 18, 2026 – Nov 6, 2026 · OTC:ESALF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $32.58 | 0.00 | 0.0% | $32.58 | $32.58 | $32.58 | 0 | |
| $32.58 | +2.61 | +8.7% | $32.58 | $32.58 | $32.58 | 500 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | 0.00 | 0.0% | $29.97 | $29.97 | $29.97 | 0 | |
| $29.97 | -0.82 | -2.7% | $29.97 | $29.97 | $29.97 | 200 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | 0.00 | 0.0% | $30.79 | $30.79 | $30.79 | 0 | |
| $30.79 | +1.79 | +6.2% | $30.79 | $30.79 | $30.79 | 300 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | 0.00 | 0.0% | $29.00 | $29.00 | $29.00 | 0 | |
| $29.00 | -1.50 | -4.9% | $29.00 | $29.00 | $29.00 | 100 | |
| $30.50 | 0.00 | 0.0% | $30.50 | $30.50 | $30.50 | 0 | |
| $30.50 | 0.00 | 0.0% | $30.50 | $30.50 | $30.50 | 0 | |
| $30.50 | -1.00 | -3.2% | $32.00 | $32.00 | $30.50 | 500 | |
| $31.50 | -0.05 | -0.2% | $31.50 | $31.50 | $31.50 | 13,900 | |
| $31.55 | 0.00 | 0.0% | $31.55 | $31.55 | $31.55 | 0 | |
| $31.55 | 0.00 | 0.0% | $31.55 | $31.55 | $31.55 | 0 | |
| $31.55 | 0.00 | 0.0% | $31.55 | $31.55 | $31.55 | 425 | |
| $31.55 | +0.94 | +3.1% | $31.25 | $31.55 | $31.25 | 2,300 | |
| $30.61 | -0.39 | -1.3% | $31.25 | $31.25 | $30.61 | 400 | |
| $31.00 | -1.00 | -3.1% | $31.00 | $31.00 | $31.00 | 100 | |
| $32.00 | +2.10 | +7.0% | $32.00 | $32.00 | $32.00 | 628 | |
| $29.90 | +1.195 | +4.2% | $29.90 | $29.90 | $29.90 | 110 |
Splits
2 splits since 1992 · OTC:ESALF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split | |
| 11-for-10 | Split |
- Ticker
- OTC:ESALF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Now Available in Japan for Patients with Early Alzheimer’s Disease
Latest earnings call · Aug 3, 2026
Eisai (Tokyo:4523) Q1 2027 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Q2 2027 Earnings Presentation
Earnings · 33 slides
Latest news
Revenue of LEQEMBI (Preliminary Basis)
Oct 28, 2026
Closed $29.97 (0.0%) on Oct 28, 2026
Notification Regarding Receipt of Dividend from a Consolidated Subsidiary
Oct 2, 2026
Closed $30.50 (0.0%) on Oct 2, 2026
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Sep 25, 2026
Closed $31.55 (0.0%) on Sep 28, 2026
Leqembi® Pen subcutaneous formulation approved in Japan
Sep 16, 2026
Closed $31.55 (+3.1%) on Sep 18, 2026
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Sep 16, 2026
Closed $31.55 (+3.1%) on Sep 18, 2026
Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
Sep 15, 2026
Closed $31.55 (+3.1%) on Sep 18, 2026
Eisai Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 59 in the last 12 months · 89 in all · newest Nov 12, 2026 · oldest 2025
- Calls
- 8 calls with a replay · 8 with a transcript · latest Aug 3, 2026
- Decks
- 9 decks · latest Nov 10, 2026
Where Eisai Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4523 エーザイ · Home listing | Tokyo | Japan | JPY |
| OTC:ESAIY | OTC | United States | USD |
| gettex:EII | gettex | Germany | EUR |
| OTC:ESALF · This page | OTC | United States | USD |
| Tradegate:EII | Tradegate | Germany | EUR |
| LS Exchange:855526 | LS Exchange | Germany | EUR |
| Frankfurt:EII | Frankfurt | Germany | EUR |
| Lang & Schwarz:855526 | Lang & Schwarz | Germany | EUR |
| Hamburg:EII | Hamburg | Germany | EUR |
| Hanover:EII | Hanover | Germany | EUR |
| Munich:EII | Munich | Germany | EUR |
| Dusseldorf:EII | Dusseldorf | Germany | EUR |
| BIVA:4523N | BIVA | Mexico | MXN |
| BMV:4523N | BMV | Mexico | MXN |
| Dusseldorf:EIIA | Dusseldorf | Germany | EUR |
| Frankfurt:EIIA | Frankfurt | Germany | EUR |
| Stuttgart:EII | Stuttgart | Germany | EUR |
Team and board
| Officer | Role |
|---|---|
| Eisai Co | Ltd. Investor Relations Department |
| Jenny Ljunggren | External Communications and Investor Relations ManagerE-mail: [email protected] |
| Oskar Bosson | VP Communications and Investor RelationsE-mail: [email protected] |
Events
| Call | When | Status |
|---|---|---|
| Eisai (Tokyo:4523) Q1 2027 Earnings Call | Mon, Aug 03, 2026 · 3:00 AM ET | Replay |
| Eisai (Tokyo:4523) Q4 2026 Earnings Call | Fri, May 15, 2026 · 3:00 AM ET | Replay |
| Eisai (Tokyo:4523) Q2 2026 Earnings Call | Fri, Nov 07, 2025 · 2:30 AM ET | Replay |
| Eisai (Tokyo:4523) Q1 2026 Earnings Call | Tue, Aug 05, 2025 · 2:30 AM ET | Replay |
| Eisai (Tokyo:4523) Q4 2025 Earnings Call | Thu, May 15, 2025 · 2:30 AM ET | Replay |
| Eisai (Tokyo:4523) Q2 2025 Earnings Call | Fri, Nov 08, 2024 · 1:00 AM ET | Replay |
| Eisai (Tokyo:4523) Q1 2025 Earnings Call | Fri, Aug 02, 2024 · 2:00 AM ET | Replay |
| Eisai (Tokyo:4523) Q4 2024 Earnings Call | Thu, May 16, 2024 · 2:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2027 Earnings Presentation | Earnings | 33 slides | Nov 10, 2026 |
| Q2 FY2026 Earnings Presentation | Earnings | 33 slides | Nov 10, 2026 |
| Q1 2027 Earnings Presentation | Earnings | 30 slides | Aug 3, 2026 |
| FY2025 Earnings Presentation | Earnings | 37 slides | May 15, 2026 |
| Corporate Update (November 2025) | Corporate update | 22 slides | Nov 13, 2025 |
| Q2 2026 Earnings Presentation | Earnings | 37 slides | Nov 7, 2025 |
| Fact Sheet (May 2014) | Fact sheet | 1 slide | May 2014 |
| Fact Sheet (March 2013) | Fact sheet | 1 slide | March 2013 |
| Fact Sheet (June 2011) | Fact sheet | 2 slides | June 2011 |
Filings
Cap table
Built by 6ix from Eisai Co., Ltd.’s releases
- Common shares
- 291,649,149
- Fully diluted
- 291,649,149
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 291,649,149 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 291,649,149 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eisai Co Other companies: Nuvation Bio Inc. (Ltd. Investor Relations Department · Since at least Mar 26, 2026); Biogen Inc. (Investor Relations Department · Since at least Jan 25, 2026) | Ltd. Investor Relations Department · Since at least Mar 26, 2026 |
| Jenny Ljunggren | External Communications and Investor Relations ManagerE-mail: [email protected] · Since at least Sep 16, 2026 |
| Oskar Bosson | VP Communications and Investor RelationsE-mail: [email protected] · Since at least Sep 16, 2026 |
Log in to ask 6ix AI your own questions about Eisai Co., Ltd.